Opus Genetics, Inc. (IRD) Stock Price & How to Invest
Last updated July 2026
Short answer
IRD is Opus Genetics, a Durham, North Carolina ophthalmology biotech that trades on the Nasdaq Capital Market, and it is bought the way a clinical-stage gene therapy company is bought: as a claim on a small number of binary readouts, not on the roughly $9.9 million of trailing revenue, which is mostly reimbursement from a partner rather than product sales. Anyone building a position is effectively underwriting two things, an FDA decision on a presbyopia eye drop due in October 2026 and a Phase 3 gene therapy for a rare form of childhood blindness reading out at the end of 2027.
IRD stock price
As of 2026-09-09, Opus Genetics, Inc. (IRD) last closed at $5.73, up 330.8% over the past year. Over the past 52 weeks it has traded between $1.33 and $5.75.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Opus Genetics, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Opus Genetics, Inc. (IRD) do?
Opus Genetics develops treatments for eye disease, and it does so along two tracks that have very little to do with each other. The first is a portfolio of AAV gene therapies for inherited retinal diseases, which is where the ticker comes from: IRD is the industry abbreviation for inherited retinal disease. The lead program, OPGx-LCA5, is in a registrational Phase 3 trial for LCA5-associated blindness and carries FDA Rare Pediatric Disease, Orphan Drug and RMAT designations. Behind it sit OPGx-BEST1 for bestrophin-1 related retinal disease, plus earlier programs targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The second track is phentolamine ophthalmic solution 0.75%, which is already FDA-approved and sold by Viatris as RYZUMVI for reversing dilated pupils after an eye exam, and which is under FDA review for a much larger presbyopia indication with a target action date of October 17, 2026. The company was formed when Ocuphire Pharma acquired the private Opus Genetics in late 2024 and took its name, which is why the SEC filer history runs back through Ocuphire and Rexahn.
The investment picture is the standard clinical-stage one, with an unusually crowded near-term calendar. Revenue in the first half of 2026 was about $2.9 million against about $7.3 million a year earlier, and almost all of it is Viatris reimbursing Opus for development work rather than a royalty stream that scales, so the trailing figure will keep shrinking as those programs finish. Operating losses are running near $16 million a quarter as manufacturing and Phase 3 costs ramp. Against that, the balance sheet is better funded than most companies this size: roughly $89 million of cash at June 30, 2026 plus roughly $120 million still available under a note purchase agreement with Oberland Capital, which management says funds operations into 2029. The share count moved from about 70 million at the end of 2025 to about 83 million by September 2026, and a fresh S-3 shelf was filed in August 2026, so dilution is an ongoing feature rather than a one-off. On September 9, 2026 the stock rose more than 50 percent on positive early data from the OPGx-BEST1 Phase 1/2 trial, which is a fair illustration of how the shares behave around news.
What's driving Opus Genetics, Inc. (IRD)?
1. The presbyopia decision on October 17, 2026
Phentolamine ophthalmic solution 0.75% is already approved as RYZUMVI for a narrow diagnostic use, and Opus has an sNDA under review to extend it to presbyopia, the age-related loss of near vision that affects a very large share of adults over 45. The VEGA-2 and VEGA-3 trials both met their primary and key secondary endpoints, with the effect described as lasting up to 20 hours. Viatris holds exclusive US commercial rights, so an approval reaches Opus as milestones and royalties rather than as a sales line the company controls.
2. OPGx-LCA5 is in a registrational trial with a defined path
Enrollment in the Phase 3 registrational trial completed in August 2026, dosing with commercial-grade material was guided to begin in the fourth quarter of 2026, and topline data is targeted for the end of 2027. The trial design was worked out with the FDA and is intended to support a Biologics License Application. The RMAT and Rare Pediatric Disease designations matter here, because the latter can carry a priority review voucher that companies have historically sold for well over $100 million.
3. OPGx-BEST1 turned into a second real program in September 2026
Three- and six-month results from the low-dose Cohort 1 of the BIRD-1 Phase 1/2 trial showed visual acuity gains in 60 percent of participants and retinal sensitivity gains in 75 percent of evaluable participants, with no serious adverse events or intraocular inflammation. Opus met the FDA in August 2026 and aligned on a randomized Phase 3 using microperimetry plus a patient-reported outcome as the primary endpoint, with dosing planned for 2027. Survey work cited by the company puts the global symptomatic BEST1 population near 45,400, larger than earlier estimates.
4. A funded runway in a sector where financing is the usual failure mode
Cash of roughly $89 million at June 30, 2026 plus roughly $120 million still drawable from Oberland Capital gives management the confidence to guide to operations funded into 2029. That is unusual for a company of this size and removes the most common reason small biotechs issue equity into weakness. It does not remove dilution risk, since the share count still rose about 18 percent in six months and a new shelf registration was filed in August 2026.
What are the risks to Opus Genetics, Inc. (IRD)?
The trailing numbers do not support the valuation on any conventional measure, so essentially all of the market capitalization rests on events that have not happened yet. The BEST1 data that moved the stock more than 50 percent came from five patients in an open-label, uncontrolled cohort, and single-arm improvements in small numbers of retinal patients have historically failed to replicate in randomized trials. Revenue is falling rather than growing, because it is Viatris reimbursing development costs rather than product sales, and the phentolamine franchise is commercially controlled by Viatris, so Opus captures only royalties and milestones from whatever the drug becomes. The October 17, 2026 PDUFA date is a genuine binary: a complete response letter would remove the nearest source of non-dilutive cash. Inherited retinal disease markets are also very small in patient count and expensive to serve, AAV gene therapy carries a long industry history of manufacturing and immune-response setbacks, and the Oberland facility is debt-like capital whose obligations sit ahead of shareholders.
What is the Opus Genetics, Inc. (IRD) forecast?
17 analysts publish price targets on IRD, averaging $10.71 against a $5.73 price as of September 2026, or +86.9%. The published targets run from $8.00 to $16.00, a wide spread, and the ratings split 18 buy, 0 hold, 0 sell. Over the last six months there have been 2 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full IRD forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is IRD a buy or a sell?
We give no verdict on Opus Genetics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. The presbyopia decision on October 17, 2026. Phentolamine ophthalmic solution 0.75% is already approved as RYZUMVI for a narrow diagnostic use, and Opus has an sNDA under review to extend it to presbyopia, the age-related loss of near vision that affects a very large share of adults over 45. The most optimistic published target, $16.00, assumes this works close to its best case.
The case against. The trailing numbers do not support the valuation on any conventional measure, so essentially all of the market capitalization rests on events that have not happened yet. The most pessimistic target, $8.00, is roughly what IRD is worth if this bites instead.
Read the full bull and bear case on IRD, including what would have to change to break either one. Walnut is not an investment adviser.
How is Opus Genetics, Inc. (IRD) valued? (approximate, September 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Opus Genetics, Inc.'s investor relations page or your broker.
- Market cap: ~$580M after the September 9, 2026 move (~$480M before it)
- Share price: ~$7.00, a 52-week high, against a 52-week low of ~$1.32
- Revenue (TTM): ~$9.9M, almost entirely Viatris collaboration reimbursement
- Q2 2026 revenue: ~$0.8M, down from ~$2.9M in Q2 2025
- Q2 2026 operating loss: ~$16M (R&D ~$11.2M, G&A ~$6.0M)
- Cash and runway: ~$89M at June 30, 2026, plus ~$120M available from Oberland Capital, guided into 2029
No revenue multiple is informative here, because the roughly $9.9 million trailing figure is a development-cost reimbursement that shrinks as programs complete, not a commercial ramp. What the market is pricing instead is the presbyopia royalty stream if the October 2026 sNDA clears, the LCA5 Phase 3 asset, and the newly de-risked BEST1 program, against roughly 83 million shares and a balance sheet that does not force a near-term raise. Sell-side coverage as of early September 2026 clustered around a mean target near $10.71, with Wedbush at $13 and RBC at $9 while explicitly flagging speculative risk, which is a reasonable description of the spread of outcomes.
Who competes with Opus Genetics, Inc. (IRD)?
Inherited retinal disease gene therapy
The direct comparison set. Novartis and Spark's Luxturna, approved for RPE65 mutations, remains the only FDA-approved gene therapy for an inherited retinal disease and is the commercial precedent every company here is measured against. Active developers include Beacon Therapeutics and MeiraGTx in X-linked retinitis pigmentosa, Atsena Therapeutics in LCA1 and Usher syndrome, Nanoscope Therapeutics with an optogenetic approach for retinitis pigmentosa, and Ocugen, whose modifier-gene strategy aims at multiple mutations at once rather than one gene per program. Each targets a small population, which limits direct overlap but concentrates competition for trial sites, patients and payer attention.
Presbyopia and pupil-modulating eye drops
Where the phentolamine franchise actually competes, and where Viatris rather than Opus carries the commercial burden. AbbVie and Allergan's Vuity was the first pilocarpine-based presbyopia drop, LENZ Therapeutics won approval for an aceclidine drop, Orasis markets a low-dose pilocarpine option, and Tenpoint has a combination candidate. This category has a track record of approvals that did not convert into large sales, so approval and commercial success are separate questions.
Large ophthalmology pharma
Regeneron, Roche and Genentech, Novartis, AbbVie, Bausch and Lomb, Alcon and Astellas dominate eye care commercially and control the prescriber relationships and specialty distribution that a company with 27 employees cannot build alone. For a developer of Opus's size they function less as head-to-head rivals than as the eventual partners or acquirers, which is a large part of why small ophthalmology assets are valued the way they are.
What stocks are similar to Opus Genetics, Inc. (IRD)?
Other names that sit close to IRD: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.
How to invest in Opus Genetics, Inc. (IRD)
There are three common ways to get IRD exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so IRD sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where IRD fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Opus Genetics, Inc. (IRD)
Opus Genetics is a real drug developer with an approved partnered product and a Phase 3 asset, not a shell, but at roughly $580 million the market is paying almost entirely for pipeline outcomes that are still years and several readouts away.
More on Opus Genetics, Inc. (IRD)
Whether IRD is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is IRD a buy or a sell?, and where the stock could go from here in the IRD stock forecast.
For income investors, whether IRD pays a dividend and how the payout looks is covered in does IRD pay a dividend? And to weigh IRD against a peer, read the full side-by-side comparisons: IRD vs NVS and IRD vs OCGN.
Wondering how IRD fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Opus Genetics, Inc. with AI
Connect the broker you already use and ask Walnut's AI how IRD fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What company trades under the ticker IRD?
+
IRD is Opus Genetics, Inc., listed on the Nasdaq Capital Market and headquartered in Durham, North Carolina. The ticker is a reference to inherited retinal disease, the company's main therapeutic focus. It files with the SEC under CIK 0001228627, a filer history that runs back through Ocuphire Pharma and Rexahn Pharmaceuticals, since the current company was formed when Ocuphire acquired the private Opus Genetics in late 2024 and adopted its name.
Does Opus Genetics have an approved product?
+
Yes, though indirectly. Phentolamine ophthalmic solution 0.75% is FDA-approved and sold as RYZUMVI for reversing pharmacologically-induced pupil dilation after an eye exam. Viatris holds exclusive US commercial rights under a licensing agreement, so Opus receives royalties and milestones rather than booking product sales. Everything else in the company's pipeline, including all of the gene therapy programs, remains investigational.
Why is the revenue so small relative to the market capitalization?
+
Trailing revenue of roughly $9.9 million is almost entirely Viatris reimbursing Opus for research and development services under their license agreement, plus a small amount of RYZUMVI royalty. It is a cost recovery line, not a commercial ramp, and it declines as programs finish, which is why first-half 2026 revenue of about $2.9 million was down from about $7.3 million a year earlier. Clinical-stage biotech valuations are set by pipeline expectations rather than by current revenue.
What happened to the stock on September 9, 2026?
+
Opus reported three- and six-month results from the low-dose first cohort of BIRD-1, its Phase 1/2 trial of OPGx-BEST1, and the shares rose more than 50 percent to a 52-week high on volume roughly 25 times the recent average. All five participants showed visual function improvement, four of five showed structural improvement, and there were no serious adverse events or intraocular inflammation. The company also disclosed FDA alignment on a Phase 3 design, with dosing planned for 2027.
What is the next scheduled catalyst?
+
The FDA has a target action date of October 17, 2026 on the supplemental New Drug Application to extend phentolamine ophthalmic solution 0.75% to presbyopia. After that, dosing in the OPGx-LCA5 Phase 3 registrational trial was guided to begin in the fourth quarter of 2026, OPGx-RDH12 was expected to enter the clinic in the same window, and topline three-month data from the higher-dose BEST1 cohort was guided to the second quarter of 2027.
How long can Opus Genetics fund itself?
+
The company reported roughly $89 million in cash and equivalents at June 30, 2026 and has roughly $120 million still available under a note purchase agreement with Oberland Capital Management. Management stated that these aggregate resources fund operations into 2029. That is a longer runway than most companies of this size carry, though the Oberland facility is debt-like capital with obligations that rank ahead of common shareholders.
How much dilution has there been?
+
Shares outstanding went from about 69.9 million at December 31, 2025 to about 82.6 million at June 30, 2026, roughly 18 percent in six months, and the count stood near 83.2 million in early September 2026. Opus also filed a new S-3 shelf registration in August 2026, which keeps the option to issue more stock open. Ongoing dilution is the normal financing pattern for a company running roughly $16 million of quarterly operating losses with no product sales of its own.
How would someone hold IRD inside a thematic basket?
+
In Walnut it would sit inside a basket built around a stated thesis, gene therapy for rare disease or small-cap ophthalmology for example, with a target weight written down before any order is placed. That matters more than usual for a stock that moved more than 50 percent in one session and carries a scheduled FDA decision, because a position sized for a single binary outcome behaves very differently from a position sized as one name among many. Walnut tracks the actual shares bought through a basket against those targets and does not recommend any particular allocation.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Opus Genetics, Inc.'s investor relations page or your broker before making investment decisions.